Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject will be between 18 to 80 years of age.~2. Subject has not been on Gralise.~3. Subject has not been on gabapentin for at least one month.~4. Subject agrees to make no change in his/her current pain medications during the study period to ensure that comparisons can be made before and after the Gralise treatment.~5. Subject has a VAS pain score of 5 or above at the beginning of the study.~6. Subject has had CRPS I for at least three months to avoid clinical uncertainty and minimize the study variation.~7. Female subjects of childbearing age must have a negative urine pregnancy test at the initial visit.~Exclusion Criteria:~1. Subject has severe liver or renal disease that will affect the elimination of Gralise. (Renal dysfunction is defined as eGFR \< 60. Hepatic dysfunction is defined as LFTs ≥ 3X ULN.)~2. Subject has pending litigation related to his/her CRPS I condition.~3. Subject is pregnant or lactating.~4. Subject is allergic to gabapentin or Gralise.~5. Subject has a positive urine (illicit) drug test.~6. Subject has any history of suicidal thoughts or behaviors, as self reported or in documented medical history.~7. Subjects with known seizure disorders (except febrile seizures) and/or taking antiepileptic drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- CRPS I Pain Subjects (Type: EXPERIMENTAL): This is an open label study that involves taking Gralise pills (gastic-retentive gabapentin) for 8 weeks.~Day 1-15: Titration phase- titrate Gralise from 300 mg/day to 1800 mg/day Day 16-42: Maintenance phase- maintain the dose of 1800 mg/day Day 43-56: Taper phase- taper the Gralise from 100 mg/day to 300 mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).